Increasing HCV treatment in primary care is crucial to achieving HCV elimination in Australia by 2030. This course aims to empower general practitioners, nurse practitioners and other prescribing practitioners with the skills and confidence to diagnose, assess, manage, and treat HCV in primary care.
Training delivery utilises a blended learning approach with expert-led presentations and facilitated case discussions delivered by specialists, General Practitioners, Nurse Practitioners and Peer/Lived Experience workforce with expertise in HCV management and treatment.
Click here to view the flyer.
Date, Time, Platform:
Date: Thursday, 28th May 2026
Time: 6:00pm – 8:00pm (AEST)
Platform: Online – Zoom
Presenters:
- Dr David Baker – General Practitioner | East Sydney Doctors
- Hayley Thompson – Nurse Practitioner | QuIHN
- Esha Leyden – Peer Harm Reduction Coordinator | QuIHN
Learning Outcomes:
On completion of this course and its components, participants will be able to:
- Identify when screening and testing for HCV is indicated
- Interpret HCV test results
- Discuss required pre-treatment assessments
Course Components:
- Clinical Extensions of Hep C Online Learning Module
- One two-hour online workshop
Recommended Resources:
CPD & Endorsement:
- RACGP: This course has been approved as a CPD activity by RACGP for the 2023-2025 triennium. Educational Activities: 1.5 Educational Activity hours. Reviewing Performance: 1.0 Reviewing Performance hours. RACGP Activity Number: 891606
- ACCRM: This course has been approved by ACRRM as an accredited activity. Allocated total XX PDP units:1.5 Educational Activity hours. Reviewing Performance: 1.0 Reviewing Performance hours.
- Clinical Extensions of Hepatitis C (Optional Pre-Course Activity)
- GPs completing the optional pre-course activity will be awarded the approved 1 Educational Activity hours in the 2023-2025 RACGP Triennium.
Funding:
This activity is funded by Queensland Health.
Target Audience:
General practitioners, nurse practitioners, other practitioners prescribing or intending to prescribe s85 direct-acting antiviral medication for HCV in primary care settings in Australia. Nurses involved in the assessment and work-up of patients for treatment are also encouraged to attend.
